InnoMed - AddNeuroMed

 Is using the consortium’s expertise in analytical techniques, pre-clinical and clinical development to provide technologies to facilitate and accelerate the delivery of safe and effective medicines whilst addressing the issues of:
• Absence of diagnostic markers,
• Lack of biomarkers of progression, and
• Lack of biomarkers of response/non-response.

The project is aimed specifically at the discovery and validation of new markers for diagnostics, disease progression and therapeutic efficacy, and may lead to improved animal models of Alzheimer Disease as a by-product. The research design details are specific for Alzheimer.

Disease but the progression from in vitro to animal testing to the clinic is a blueprint for how similar approaches might be undertaken for other major diseases.

Studies are underway to generate models for biomarker discovery in mice, rat and drosophila, and in the human studies assessment protocols have been established, neuro-imaging routines tested and the first patients have been recruited.

For more information, see the InnoMed-AddNeuroMed Project Web Site.